Organogenesis Holdings (ORGO) Stock Analysis & Winston Score

Organogenesis Holdings makes advanced wound care products — special skin substitutes and regenerative medicine treatments that help heal difficult wounds. Its main products include Apligraf and Dermagraft, which are bioengineered skin grafts used to treat chronic wounds like diabetic foot ulcers and venous leg ulcers. The company sells primarily to hospitals, wound care clinics, and physicians across the United States. The company earns revenue by selling its wound care products directly to healthcare providers, with reimbursement from Medicare and private insurers playing a big role in how much it gets paid. Organogenesis operates almost entirely in the US market and generates roughly $500 million in annual revenue, giving it a meaningful presence in the advanced wound care space. Its high gross margin reflects the premium pricing of bioengineered products, but the company is not yet consistently profitable, and its biggest risk is reimbursement policy changes — if Medicare cuts coverage or payment rates for its products, revenue could fall sharply.